9:01 AM
 | 
Jan 11, 2019
 |  BC Week In Review  |  Company News  |  Deals

Genentech, Adaptive Biotechnologies to develop cancer T cell therapies

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Genentech Inc. partnered to develop personalized and off-the-shelf T cell therapies for a broad range of cancers using Adaptive's TruTCR discovery and immune profiling platform. TruTCR combines immunosequencing, cellular...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >